© Copyright 2004-2018 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        


PharmaInformatic provides
ADME Knowledge Bases
 and Expert Systems
for drug discovery
and toxicological
risk assessment.
 


DGPT 2018:
Our current
research project
EXITOX-II
(Animal-free toxicity testing)
is presented at
German Pharm-Tox Summit 2018
 





The company was founded in 2004 and is based in Emden, Germany.


  Get In Contact

    LinkedIn   Twitter


Unsere Technologien
 ersetzen Tierversuche
 in der Medikamenten-Entwickung
und bei toxikologischen Untersuchungen

 


New Collaboration:
 

CRACK IT DoCE Challenge
 

Sponsored by Unilever and Shell, this challenge aims to develop methods and tools that will better quantify and control the exposure of chemicals for predicting in vivo toxicity in order to replace animal testing (more).


 

New technology to evaluate Plasma Protein Binding of compounds by Artificial Intelligence:

PharmaInformatic develops a large and comprehensive annotated knowledge base on Plasma Protein Binding of compounds. It now contains more than 17.000 data records taken from more than 2.400 scientific publications. The technology improves toxicity assessment of compounds and discovery of new drugs. A current validation study showed a high quality of prediction (more).

 

IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F evaluates oral bioavailability of future drugs in humans. The technology is used to optimise lead candidates. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. (research results).

 


Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail. Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.


Our research replaces animal tests
A large number of animal trials is carried out every day to select and optimise drug compounds. New effective drugs must be taken up into the human body ("oral bioavailability") otherwise itís a waste of time, money and resources. The expert system IMPACT-F evaluates oral drug uptake significantly more reliably than animal tests. Pharmaceutical companies use the technology to optimise the development of novel drugs (see customers testimonials).